An investigation into the carbon and material footprint of the Dutch consumption of pharmaceuticals

This thesis explores the relatively large contribution of the product category ‘chemicals n.e.c.’ (chemicals not elsewhere classified) to the Dutch healthcare sector’s carbon and material footprint observed in previous studies. For this, an input-output study using SNAC-EXIOBASE data was performed. SNAC-EXIOBASE uses national statistics for the...

R&D productivity and disruptive innovation: An empirical analysis of the emerging biotechnology sector

The R&D productivity crisis is among the most pressing issues in the drug industry. The increasing costs and stable R&D outputs jeopardise the industry’s economic health, drug innovation, and the accessibility and affordability of medicines. The pharmaceutical R&D productivity problem is expected to be diminished due to...

Pharma, Finance and Freedom: Alternative Perspectives on Financing the Development and Production of Medicines

Market access for small ventures in the pharmaceutical industry

Looking for the Healing Innovation Process: An Explorative Study on the Critical Sucess Factors for Innovation Management in the Pharmaceutical Industry

The pharmaceutical industry has been spending an increasing amount of money on R&D over the years. However, fewer drugs have been approved by the FDA and the EMA recently. This lack in innovation performance is a problem which needs to be solved in order to continue finding medicines for cureless diseases. Innovation lies at the heart of the...

R&D productivity in the pharmaceutical industry. Scenario simulations using a Bayesian belief network

The pharmaceutical industry is in a R&D productivity crisis. Rapidly increasing development costs, decreasing profitability of new medical entities and missing breakthrough innovation are afflicting the future of the pharmaceutical industry. This complex problem requires a systems thinking approach. In this study, we ought to map the general...